Photo from archive.org
The PD-1 inhibitor nivolumab given prior to surgical removal of early-stage non-small cell lung cancer is safe and produces a high rate of pathologic response, especially among those with high… Click to show full abstract
The PD-1 inhibitor nivolumab given prior to surgical removal of early-stage non-small cell lung cancer is safe and produces a high rate of pathologic response, especially among those with high tumor mutation burden.
Keywords:
checks lung;
nivolumab checks;
neoadjuvant nivolumab;
lung cancer;
cancer
Journal Title: Cancer discovery
Year Published: 2018
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Cancer discovery
Year Published: 2018
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!